Shanghai Jingfeng raises RMB190 million

Shanghai Jingfeng Pharmaceutical Co. Ltd. (Shanghai, China) raised RMB190 million ($30.4 million) in a series A round, including RMB100 million ($16 million) from Vivo Ventures. The investment is Vivo's first in China since receiving a license in September under the country's pilot Qualified Foreign Limited Partner (QFLP) program, which allows licensed foreign firms to invest a capital that can be converted immediately into renminbi (see BioCentury, Sept. 17). ...